Decreased Expression of microRNA-451 is Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia Patients

被引：0
|
作者：
Khalifa, Khaled [1 ]
Abbas, Omaima [2 ]
Abdlfattah, Raafat [3 ]
Alhassanin, Suzan [4 ]
Shehata, Amira [1 ]
Esawy, Sally [2 ]
机构：
[1] Menoufia Univ, Dept Clin Pathol, Fac Med, Shibin Al Kawm, Egypt
[2] Menoufia Univ, Natl Liver Inst, Dept Clin Pathol, Shibin Al Kawm, Egypt
[3] Cairo Univ, Natl Canc Inst, Dept Med Oncol, Cairo, Egypt
[4] Menoufia Univ, Dept Clin Oncol, Fac Med, Shibin Al Kawm, Egypt
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷
关键词：
imatinib mesylate; microRNA-451; real-time polymerase chain reaction; CML; chronic myelogenous leukemia;
D O I：
10.1016/j.clml.2019.07.240
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CML-165
引用
收藏
页码：S293 / S293
页数：1
相关论文
共 50 条
  • [21] Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel
    Yamazaki, Rie
    Aisa, Yoshinobu
    Mori, Takehiko
    Iketani, Osamu
    Ikeda, Yasuo
    Okamoto, Shinichiro
    LEUKEMIA & LYMPHOMA, 2009, 50 (04) : 670 - 672
  • [22] Cytogenetic responses in chronic myeloid leukemia patients treated with imatinib mesylate
    Babameto-Laku, A.
    Mokin, V.
    Cikuli, M.
    Xhumari, P.
    CHROMOSOME RESEARCH, 2005, 13 : 158 - 158
  • [23] Imatinib mesylate, a new drug for chronic myeloid leukemia in pediatric patients
    Thavaraj, Vasantha
    Seth, Rachna
    WORLD JOURNAL OF PEDIATRICS, 2007, 3 (02) : 110 - 114
  • [24] Nutritional Status of Patients with Chronic Myeloid Leukemia Treated with Imatinib Mesylate
    Jose Castillo-Martinez, Maria
    Juventina Tuna-Aguilar, Elena
    del Pilar Milke-Garcia, Maria
    Camacho Zamora, Anais
    Villegas Cervantes, Viviana
    Castillo-Martinez, Lilia
    NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 2022, 74 (09): : 3211 - 3216
  • [25] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [26] Downregulation of miR-451 in Tunisian chronic myeloid leukemia patients: potential implication in imatinib resistance
    Soltani, Ismael
    Douzi, Kais
    Gharbi, Hanen
    Benhassine, Islem
    Teber, Mouheb
    Amouri, Hassiba
    Othman, Hind Ben Hadj
    Farrah, Ahlem
    Ben Lakhel, Raihane
    Abbes, Salem
    Menif, Samia
    HEMATOLOGY, 2017, 22 (04) : 201 - 207
  • [27] Results of imatinib mesylate therapy in chronic myeloid leukemia
    Altintas, Abdullah
    Cil, Timucin
    Ayyildiz, Orhan
    Kaplan, Mehmet A.
    Isikdogan, Abdurrahman
    Muftuoglu, Ekrem
    Atay, Ahmet E.
    ANNALS OF ONCOLOGY, 2006, 17 : 211 - 211
  • [28] The unfolding story of imatinib mesylate for chronic myeloid leukemia
    Goldman, John M.
    ONCOLOGY-NEW YORK, 2007, 21 (06): : 663 - 664
  • [29] Kaposi's sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
    D'Addona, Matteo
    Pezzullo, Luca
    Giudice, Valentina
    Serio, Bianca
    Baldi, Carlo
    Zeppa, Pio
    Selleri, Carmine
    CLINICAL CASE REPORTS, 2022, 10 (06):
  • [30] Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response
    Osorio, S.
    Noblejas, A. Garcia
    Duran, A.
    Steegmann, J. L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (05) : 394 - 395
12345